Uterine Sarcoma

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Overview

If you have uterine sarcoma, your outcomes are likely to be better if a gynecologic oncologist treats you right from the beginning.

Seattle Cancer Care Alliance (SCCA) has more gynecologic oncologists than any other medical center or clinic in the Pacific Northwest. They treat all types of gynecologic cancer, including uterine sarcoma, endometrial cancer, cervical cancer, ovarian cancer, vulvar cancer, and gestational trophoblastic disease.

Where You’re Treated First Matters Most

The most important decision a person with cancer will make is deciding where to get treatment. Studies have shown that patients who begin their treatment at a top regional cancer center, like SCCA, have better outcomes than those who start their treatment elsewhere. And here’s why.

Expert Care

SCCA doctors treat only cancer and specialize in specific cancer types, such as gynecologic cancer. They have a deep understanding of their specialty because they diagnose and treat thousands of cancer cases every year. This experience makes better outcomes possible. Your care comes from the combined expertise of our founding organizations, Fred Hutchinson Cancer Research Center, UW Medicine, and Seattle Children’s.

Newest Treatments

Our doctors have access to the latest developments in treating cancer. SCCA was formed, in part, to bring promising new treatments to patients faster. This means more treatment options here than you might find elsewhere, like the chance to participate in clinical studies, also called clinical trials.

In the News

Read a Newsweek article that explores the differences between getting treated at a top cancer center and a local community hospital. The difference in outcomes can be striking.

Follow-Up Care

When your treatment is complete, we’ll keep close watch on your health with periodic follow-up visits. Many of our patients later go on to receive care through our Women’s Wellness Clinic, specially designed to provide follow-up care for women who are five years out from their primary treatment.